✦ LIBER ✦

Echinostoma revolutum in mice; dynamics of the antibody attack to the surface of an intestinal trematode

✍ Scribed by Paul E. Simonsen; B.Jyding Andersen

Book ID: 115945268
Publisher: Elsevier Science
Year: 1986
Tongue: English
Weight: 883 KB
Volume: 16
Category: Article
ISSN: 0020-7519
DOI: 10.1016/0020-7519(86)90083-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bioavailability of Chloroquine in Mice I

Bioavailability of Chloroquine in Mice Infected with the Intestinal Trematode Echinostoma revolutum

✍ Adan-Abdi, Yakoub ;Bindseil, Erling ;Ericsson, örjan ;Sjöqvist, Folke 📂 Article 📅 2009 🏛 Wiley (Blackwell Publishing) ⚖ 205 KB

An Attempt to Affect the Selective Absor

An Attempt to Affect the Selective Absorption of Antibodies from the Gut in Young Mice

✍ Hemmings, W. A.; Morris, I. G. 📂 Article 📅 1959 🏛 The Royal Society 🌐 English ⚖ 444 KB

An Attempt to Affect the Selective Absor

An Attempt to Affect the Selective Absorption of Antibodies from the Gut in Young Mice

✍ W. A. Hemmings and I. G. Morris 📂 Article 📅 1959 🏛 The Royal Society 🌐 English ⚖ 348 KB

Stimulatin of antibody response in the g

Stimulatin of antibody response in the gastro-intestinal mucosa of immunodeficient mice by oral treatment with bacterial antigens. An immunoperoxidase study

✍ A. Vacca; G. Pantaleo; F. Dammacco 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 838 KB

An ELISA to determine the biodistributio

An ELISA to determine the biodistribution of human monoclonal antibody in tumor-xenografted SCID mice

✍ Kenji Arai; Kaoru Yoshinari; Kunio Matsumoto; Hideo Misaki 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 128 KB

Application of pharmacokinetic–pharmacod

Application of pharmacokinetic–pharmacodynamic modeling to predict the kinetic and dynamic effects of anti-methotrexate antibodies in mice

✍ Evelyn D. Lobo; David M. Soda; Joseph P. Balthasar 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 263 KB

We have shown that intravenous (i.v.) administration of anti-methotrexate (MTX) antibodies (AMAb) reduces the systemic exposure of intraperitoneal (i.p.) MTX therapy, and we have proposed that AMAb effects on MTX systemic exposure would allow a reduction in MTX-induced systemic toxicity (i.e., produ